

Larry W Moreland

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9327888/larry-w-moreland-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234 papers	31,056 citations	69 h-index	175 g-index
253 ext. papers	35,850 ext. citations	7.2 avg, IF	6.12 L-index

#	Paper	IF	Citations
234	A review of biosimilars for rheumatoid arthritis.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102234	5.1	0
233	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022 , 11, e27273	2.1	
232	Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2021 , 73, 1372-1378	4.7	3
231	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021 , 48, 1472-1479	4.1	4
230	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021 , 3, 404-412	3.5	4
229	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. <i>Arthritis and Rheumatology</i> , 2021 , 73, 512-519	9.5	15
228	Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors. <i>Human Molecular Genetics</i> , 2021 , 30, 823-835	5.6	2
227	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021 , 16, e0244187	3.7	7
226	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 129, 114-118	2.2	2
225	Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers. <i>Journal of Diagnostic Medical Sonography</i> , 2020 , 36, 300-310	0.4	
224	B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF- β production. <i>Clinical Immunology</i> , 2020 , 212, 108360	9	9
223	Transcriptional Regulation of Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated Locus. <i>Genes</i> , 2020 , 11,	4.2	1
222	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 576-581	5.3	6
221	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 375, 488-497	4.7	0
220	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020 , 59, 1118-1127	3.9	12
219	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020 , 47, 1001-1010	4.1	9
218	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1615-1624	4.7	32

217	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38
216	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019 , 58, 2203-2211	3.9	21
215	Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. <i>Nature Immunology</i> , 2019 , 20, 928-942	19.1	369
214	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019 , 46, 928-934	4.1	3
213	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. <i>Arthritis Care and Research</i> , 2019 , 71, 521-529	4.7	14
212	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019 , 71, 1132-1140	4.7	16
211	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 707-713	5.3	21
210	Inflammatory joint diseases and atherosclerosis: time to look beyond the Cypid paradox. <i>Current Opinion in Lipidology</i> , 2019 , 30, 342-349	4.4	3
209	Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 232-236	1.1	4
208	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3B Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 319-322	4.7	1
207	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018 , 57, 322-328	3.9	20
206	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2018 , 70, 197-204	4.7	36
205	Family Planning Counseling for Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2018 , 70, 169-174	4.7	20
204	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018 , 20, 139	5.7	60
203	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 475-487	2.4	22
202	14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T2 and CD8 lymphocytes from patients with scleroderma. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 109-119.e6	11.5	11
201	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018 , 13, e0205768	3.7	5
200	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 846-853	9.5	82

199	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 837-845	9.5	155
198	Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1176-1186	9.5	27
197	Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women@ Health Initiative Rheumatoid Arthritis Study. <i>American Journal of Epidemiology</i> , 2017 , 186, 245-254	3.8	2
196	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1054-1066	9.5	85
195	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017 , 100, 64-74	11	43
194	Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 46-57	9.5	34
193	Cardiovascular Disease Risk in Patients with Rheumatic Diseases. <i>Clinics in Geriatric Medicine</i> , 2017 , 33, 105-117	3.8	14
192	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017 , 44, 11-17	4.1	16
191	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 103, 98-101	2.2	2
190	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e50	7.6	15
189	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 475-82	5.3	73
188	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12460	17.4	54
187	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1751-1757	4.7	21
186	Socioeconomic factors and self-reported health outcomes in African Americans with rheumatoid arthritis from the Southeastern United States: the contribution of childhood socioeconomic status. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 10	2.8	9
185	Reply. <i>Arthritis and Rheumatology</i> , 2016 , 68, 555-6	9.5	
184	Increased pretreatment serum IFN- γ /IL-10 ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1757-62	2.4	25
183	Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. <i>Arthritis Research and Therapy</i> , 2016 , 18, 108	5.7	36
182	Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatology</i> , 2016 , 68, 577-86	9.5	32

181	Analysis of CXCR5Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2016 , 6, 39474	4.9	14
180	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015 , 42, 1209-12	4.1	50
179	A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. <i>American Journal of Human Genetics</i> , 2015 , 96, 565-80	11	96
178	Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. <i>Arthritis Care and Research</i> , 2015 , 67, 929-39	4.7	22
177	Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women@ Health Initiative. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2311-22	9.5	43
176	Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 417	4.9	10
175	Rheumatoid arthritis in the Women@ Health Initiative: methods and baseline evaluation. <i>American Journal of Epidemiology</i> , 2014 , 179, 917-26	3.8	9
174	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014 , 506, 376-81	50.4	1426
173	Sedentary behavior and mortality in older women: the Women@ Health Initiative. <i>American Journal of Preventive Medicine</i> , 2014 , 46, 122-35	6.1	81
172	Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 785-6	2.4	4
171	Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. <i>PLoS ONE</i> , 2014 , 9, e87645	3.7	24
170	Socioeconomic disparities in the health of african americans with rheumatoid arthritis from the southeastern United States. <i>Arthritis Care and Research</i> , 2014 , 66, 1808-17	4.7	8
169	Complementary and alternative medicine use in African Americans with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 180-9	4.7	20
168	Determinants of mortality among postmenopausal women in the women@ health initiative who report rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 497-507	9.5	21
167	Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al. <i>Arthritis and Rheumatism</i> , 2013 , 65, 539-40		
166	Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1985-94		53
165	Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1812-22	4.1	27
164	Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. <i>Journal of Rheumatology</i> , 2013 , 40, 787-97	4.1	93

163	Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1430-8		107
162	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , 2013 , 9, e1003394	6	127
161	Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. <i>PLoS Genetics</i> , 2013 , 9, e1003087	6	126
160	Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial. <i>Journal of Rheumatology</i> , 2013 , 40, 572-8	4.1	18
159	Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the WomenQ Health Initiative. <i>American Journal of Epidemiology</i> , 2013 , 177, 887-93	3.8	6
158	Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1498-504	4.1	7
157	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013 , 45, 468-9	36.3	20
156	Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. <i>Arthritis and Rheumatism</i> , 2012 , 64, 655-64		24
155	Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1804-10	4.7	14
154	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2824-35		271
153	Calcium and vitamin D supplementation and incident rheumatoid arthritis: the WomenQ Health Initiative Calcium plus Vitamin D trial. <i>Rheumatology International</i> , 2012 , 32, 3823-30	3.6	22
152	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 625-39	4.7	1199
151	Inhibition of spleen tyrosine kinase for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2011 , 13, 377-8	4.9	
150	JAK inhibition in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2011 , 13, 379-80	4.9	2
149	Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2011 , 13, 381-2	4.9	
148	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 263-78	4.4	64
147	Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 625-6	2.4	19
146	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 855-66	5.1	15

145	Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R75	5.7	17
144	Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 275-81	4.1	82
143	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
142	Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. <i>Arthritis Care and Research</i> , 2010 , 62, 624-31	4.7	26
141	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1849-61		74
140	Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2219-26		25
139	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
138	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
137	A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2864-75		24
136	Associations of cigarette smoking with rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3560-8		42
135	Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3547-53		47
134	The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. <i>Journal of Medicinal Food</i> , 2009 , 12, 1143-8	2.8	29
133	An African ancestry-specific allele of CTLA4 confers protection against rheumatoid arthritis in African Americans. <i>PLoS Genetics</i> , 2009 , 5, e1000424	6	9
132	Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. <i>Clinical Infectious Diseases</i> , 2009 , 49, 924-7	11.6	69
131	Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. <i>Seminars in Arthritis and Rheumatism</i> , 2009 , 39, 132-43	5.3	48
130	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1102-11		108
129	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.		334
128	Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 309-10	4.9	

127	Certolizumab pegol in active rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 311-2	4.9	1
126	Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 313-4	4.9	1
125	REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. <i>Nature Genetics</i> , 2009 , 41, 820-3	36.3	272
124	Cytokines as targets for anti-inflammatory agents. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1182, 88-96	6.5	8
123	Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. <i>Journal of Rheumatology</i> , 2009 , 36, 736-42	4.1	100
122	The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. <i>Arthritis and Rheumatism</i> , 2008 , 58, 349-58		68
121	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008 , 58, 953-63		137
120	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1810-22		85
119	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 762-84		1118
118	Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2882-91		129
117	Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1051-66		47
116	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. <i>Clinical Immunology</i> , 2007 , 123, 235-43	9	10
115	Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate. <i>Current Rheumatology Reports</i> , 2006 , 8, 368-368	4.9	
114	Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 287-93		41
113	Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3057-9		29
112	Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. <i>Drugs and Aging</i> , 2006 , 23, 167-78	4.7	25
111	Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. <i>New England Journal of Medicine</i> , 2006 , 354, 795-808	59.2	901
110	Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. <i>Annals of Internal Medicine</i> , 2006 , 144, 865-76	8	524

109	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 11-8	2.6	7
108	Abatacept. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 185-6	64.1	138
107	Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. <i>Journal of Rheumatology</i> , 2006 , 33, 854-61	4.1	69
106	Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 2162-6	4.1	57
105	Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1245-54	5.4	32
104	Unmet needs in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005 , 7 Suppl 3, S2-8	5.7	20
103	Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 35, 197-201	5.3	77
102	Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2015-25		211
101	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2263-71		370
100	Humanized anti-interleukin-6 receptor antibody. <i>Current Rheumatology Reports</i> , 2005 , 7, 381-381	4.9	
99	Febuxostat--treatment for hyperuricemia and gout?. <i>New England Journal of Medicine</i> , 2005 , 353, 2505-7	59.2	13
98	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005 , 97, 1155-60	2.3	34
97	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005 , 32, 832-40	4.1	101
96	Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1232-42	4.1	85
95	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 1007-18	5.9	19
94	How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?. <i>Osteoarthritis and Cartilage</i> , 2004 , 12 Suppl A, S61-2	6.2	3
93	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. <i>Seminars in Arthritis and Rheumatism</i> , 2004 , 33, 249-63	5.3	43
92	Ultrasound detection of bone erosions in rheumatoid arthritis: a comparison to routine radiographs of the hands and feet. <i>Skeletal Radiology</i> , 2004 , 33, 80-4	2.7	66

91	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 333-334	4.9	4
90	Infliximab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 334-5	4.9	3
89	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1412-9		395
88	The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2750-6		140
87	Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. <i>Arthritis and Rheumatism</i> , 2004 , 51, 933-40		20
86	Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. <i>Pharmacoeconomics</i> , 2004 , 22, 39-53	4.4	49
85	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2858-68		115
84	Biologic therapies on the horizon for rheumatoid arthritis. <i>Journal of Clinical Rheumatology</i> , 2004 , 10, S32-9	1.1	14
83	Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. <i>Journal of Rheumatology</i> , 2004 , 31, 1532-7	4.1	45
82	Etanercept and methotrexate combination in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 333	4.9	1
81	Adalimumab in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 333-4	4.9	5
80	Upcoming biologic agents for the treatment of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 226-36	5.3	40
79	Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. <i>Arthritis and Rheumatism</i> , 2003 , 48, 35-45		1398
78	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003 , 49, 819-25		27
77	Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. <i>Drug Safety</i> , 2003 , 26, 23-32	5.1	26
76	Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003 , 349, 1907-15	59.2	822
75	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. <i>Clinical Therapeutics</i> , 2003 , 25, 1700-21	3.5	245
74	Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. <i>Journal of Rheumatology</i> , 2003 , 30, 691-6	4.1	53

73	Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 614-24			481
72	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1470-9			310
71	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1460-9			169
70	Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1443-50			570
69	High-resolution ultrasound for the study of target joints in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1969-70; author reply 1970-1			22
68	Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2020-8			96
67	Glucocorticoids and rheumatoid arthritis: back to the future?. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2553-63			69
66	Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2983-9			159
65	Predicting outcomes in early rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002 , 4, 193-4	4.9	2	
64	Genetic influences on rheumatoid arthritis in African Americans. <i>Immunologic Research</i> , 2002 , 26, 15-26	4.3	1	
63	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 927-35	5.9	7	
62	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001 , 44, 653-61			84
61	Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1977-83			244
60	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1984-92			227
59	TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 75-84	4	36	
58	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. <i>Arthritis Research</i> , 2001 , 3, 247-52			38
57	Potential biologic agents for treating rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 445-91	2.4	15	
56	A clinical and economic review of disease-modifying antirheumatic drugs. <i>Pharmacoeconomics</i> , 2001 , 19, 715-28	4.4	27	

55	New therapeutic approaches to the management of rheumatoid arthritis. <i>BioDrugs</i> , 2001 , 15, 379-93	7.9	15
54	Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. <i>Clinical Orthopaedics and Related Research</i> , 2001 , 130-43	2.2	109
53	Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , 2000 , 132, 871-9	8	175
52	Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000 , 6, 117-22	1.1	16
51	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2445-54		221
50	Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. <i>Clinical Therapeutics</i> , 2000 , 22, 128-39	3.5	82
49	A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2000 , 343, 1586-93	59.2	1551
48	. <i>Arthritis Research</i> , 2000 , 1, S47		78
47	The treatment of rheumatoid arthritis: a review of recent clinical trials. <i>Current Rheumatology Reports</i> , 1999 , 1, 135-8	4.9	2
46	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999 , 42, 357-65		66
45	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1194-203		261
44	Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. <i>Arthritis and Rheumatism</i> , 1999 , 12, 351-62		24
43	Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2372-80		84
42	Clinical and pharmacological experience with etanercept. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 1443-51	5.9	9
41	Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1999 , 130, 478-86	8	959
40	Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis: focus on the soluble TNF receptor p75 fusion protein, etanercept. <i>BioDrugs</i> , 1999 , 11, 201-10	7.9	3
39	The use of analgesics in the management of pain in rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , 1999 , 25, 153-91, vii	2.4	12
38	Inter-observer reliability of the arthroscopic quantification of chondropathy of the knee. <i>Osteoarthritis and Cartilage</i> , 1998 , 6, 160-6	6.2	55

37	T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1919-29		65
36	Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1998 , 24, 579-91	2.4	52
35	T-cell receptor peptide vaccination in the treatment of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1998 , 24, 641-50	2.4	10
34	Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery. <i>Rheumatic Disease Clinics of North America</i> , 1997 , 23, 981-93	2.4	29
33	Vaccination against rheumatoid arthritis: concepts and progress. <i>BioDrugs</i> , 1997 , 8, 87-95	7.9	2
32	Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. <i>New England Journal of Medicine</i> , 1997 , 337, 141-7	59.2	1375
31	Biologic agents for treating rheumatoid arthritis. Concepts and progress. <i>Arthritis and Rheumatism</i> , 1997 , 40, 397-409		121
30	Health status response of rheumatoid arthritis to treatment with DAB486IL-2. <i>Arthritis and Rheumatism</i> , 1996 , 9, 112-9		6
29	The use of methotrexate perioperatively in patients with rheumatoid arthritis undergoing major joint replacement surgery: will we ever have consensus about its use?. <i>Journal of Clinical Rheumatology</i> , 1996 , 2, 6-8	1.1	9
28	Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 257-65		85
27	Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1172-7		68
26	Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy. <i>Journal of Clinical Rheumatology</i> , 1995 , 1, 103-9	1.1	6
25	Improved methotrexate patient information. <i>Arthritis and Rheumatism</i> , 1995 , 38, 874-5		1
24	Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1177-86		56
23	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1581-8		96
22	Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. <i>Arthritis and Rheumatism</i> , 1994 , 37, 834-8		106
21	Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. <i>Annals of the New York Academy of Sciences</i> , 1993 , 696, 292-302	6.5	16
20	New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. <i>American Journal of the Medical Sciences</i> , 1993 , 305, 40-51	2.2	10

19	Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 307-18		122
18	Transforming growth factor beta within fibrotic scleroderma lungs. <i>American Journal of Medicine</i> , 1992 , 93, 628-36	2.4	22
17	Growth factors, extracellular matrix, and oncogenes in scleroderma. <i>Arthritis and Rheumatism</i> , 1992 , 35, 304-10		19
16	Rheumatoid arthritis patients and clinical drug trials. A case-control study. <i>Arthritis and Rheumatism</i> , 1991 , 4, 22-6		6
15	Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991 , 60, 412-8		36
14	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991 , 90, 295-298	2.4	33
13	Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. <i>American Journal of Medicine</i> , 1991 , 90, 295-298	2.4	70
12	Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate. <i>Arthritis and Rheumatism</i> , 1990 , 3, 53-57		
11	Cutaneous polyarteritis nodosa. <i>American Journal of Medicine</i> , 1990 , 88, 426-30	2.4	59
10	Inflammatory central nervous system involvement in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 18, 258-66	5.3	96
9	Spinal stenosis: a comprehensive review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 19, 127-49	5.3	37
8	Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 19, 31-44	5.3	62
7	Immunohistologic demonstration of type II collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1458-64		21
6	Comment on the article by Furst et al. <i>Arthritis and Rheumatism</i> , 1989 , 32, 1631-2		1
5	Intraarticular corticosteroid injections: should we rest the joints?. <i>Arthritis and Rheumatism</i> , 1989 , 2, 70-4		24
4	Viral arthritis in humans. <i>Current Opinion in Rheumatology</i> , 1989 , 1, 185-93	5.3	
3	Acute febrile neutrophilic dermatosis (Sweet syndrome): a review of the literature with emphasis on musculoskeletal manifestations. <i>Seminars in Arthritis and Rheumatism</i> , 1988 , 17, 143-53	5.3	49
2	Ludwig's Angina. <i>Archives of Internal Medicine</i> , 1988 , 148, 461		56

1	Rheumatoid Vasculitis	392-402
---	-----------------------	---------